EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... September 3, 2020 Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... June 23, 2021 HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV... October 8, 2019 Load more HOT NEWS EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Using Technology to Find Cancers Early and Exercise Improves Sexual Health...
